Pinterest Management News Today : Breaking News, Live Updates & Top Stories | Vimarsana

<p>Researchers from <a href="http://www.MDAnderson.org">The University of Texas MD&nbsp;Anderson Cancer Center</a> reported promising results in a Phase I/II trial of 37 patients with relapsed or refractory B-cell malignancies who were treated with cord blood-derived <a href="https://www.mdanderson.org/cancerwise/car-nk-therapy-offers-new-treatment-option-for-blood-cancers.h00-159379578.html">chimeric antigen receptor (CAR) natural killer (NK) cell therapy</a> targeting CD19. &nbsp;</p>

/PRNewswire/ -- Cellenkos Inc, a clinical stage biotechnology company focused on the development of allogeneic, off-the-shelf, T regulatory cell therapies...

-Clinical Trial of PRAME-Targeting Immunotherapy ISA103 in Rare Ocular Cancer to be Conducted at MD Anderson Cancer Center- OEGSTGEEST, Netherlands and HOUSTON, Jan. 4, 2023 /PRNewswire/

AFM13 in combination with NK cells shows very high overall and complete response rates in 41 heavily pre-treated CD30-positive Hodgkin lymphoma (HL) and...

MD Anderson and Empyrean announced an exclusive license and joint development agreement to advance new technologies and products in radiation oncology.